Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

Physicians 52

Physicians Marketing Patients Manufacturing 52

pharmaphorum

AUGUST 25, 2022

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years. and 18,3 months, respectively.

FDA 93

FDA Marketing Safety Patients 93

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based

Side effects 52

Side effects Patients Medical Medicine 52

European Pharmaceutical Review

AUGUST 24, 2022

1 While the first successes underscored the potential of this class of targeted therapies, they also revealed bottle?necks 2 The role of the antibody is to deliver the payload to a specific site such as a cancer cell. 5 Thus, the antibody is able to protect the payload from unwanted interactions with circulating proteins and cells.

Engineering 82

Engineering Side effects Marketing Patients 82

Pharmaceutical Technology

FEBRUARY 10, 2023

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 This is not the first treatment to come with a high price tag. Further breakdowns on RSAs are available within GlobalData’s Risk sharing database.

Marketing 105

Marketing Medicine Leads Safety 105

European Pharmaceutical Review

DECEMBER 27, 2023

Chimeric antigen receptor (CAR) T cells are the first example of a “living drug”. 1 Following in vitro production from T cells collected from a patient’s leukapheresis procedure, the CAR T cells are infused back into the patient’s blood, where they proliferate and expand. This is variable and to some extent unpredictable.

Manufacturing 83

Manufacturing Food and Drug Administration Patients Pharma 83